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Abstract
Background: Antibody-dependent cellular cytotoxicity (ADCC) has recently been identified as one of the critical
mechanisms underlying the clinical efficacy of therapeutic antibodies, especially anticancer antibodies. Therapeutic
antibodies fully lacking the core fucose of the Fc oligosaccharides have been found to exhibit much higher ADCC in
humans than their fucosylated counterparts. However, data which show how fully non-fucosylated antibodies achieve
such a high ADCC in human whole blood have not yet been disclosed. The precise mechanisms responsible for the high
ADCC mediated by fully non-fucosylated therapeutic antibodies, even in the presence of human plasma, should be
explained based on direct evidence of non-fucosylated antibody action in human blood.
Methods: Using a human ex vivo B-cell depletion assay with non-fucosylated and fucosylated anti-CD20 IgG1s rituximab,
we monitored the binding of the therapeutic agents both to antigens on target cells (target side interaction) and to
leukocyte receptors (FcγR) on effector cells (effector side interaction), comparing the intensities of ADCC in human
blood.
Results: In the target side interaction, down-modulation of CD20 on B cells mediated by anti-CD20 was not observed.
Simple competition for binding to the antigens on target B cells between fucosylated and non-fucosylated anti-CD20s
was detected in human blood to cause inhibition of the enhanced ADCC of non-fucosylated anti-CD20 by fucosylated
anti-CD20. In the effector side interaction, non-fucosylated anti-CD20 showed sufficiently high FcγRIIIa binding activity
to overcome competition from plasma IgG for binding to FcγRIIIa on natural killer (NK) cells, whereas the binding of
fucosylated anti-CD20 to FcγRIIIa was almost abolished in the presence of human plasma and failed to recruit NK cells
effectively. The core fucosylation levels of individual serum IgG1 from healthy donors was found to be so slightly different
that it did not affect the inhibitory effect on the ADCC of fucosylated anti-CD20.
Conclusion: Our results demonstrate that removal of fucosylated antibody ingredients from antibody therapeutics
elicits high ADCC in human blood by two mechanisms: namely, by evading the inhibitory effects both of plasma IgG on
FcγRIIIa binding (effector side interaction) and of fucosylated antibodies on antigen binding (target side interaction).
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Background
The clinical successes of therapeutic antibodies have been
demonstrated by improvement of overall survival and
time to disease progression in various types of malignant
diseases, such as breast, colon, and hematological cancer
[1-5]. As molecular-targeted therapeutics, therapeutic
antibodies that bind to specific cell-surface antigens on
target cells can induce cytotoxicity via the effector func-
tions of antibody-dependent cellular cytotoxicity (ADCC)
and complement-dependent cytotoxicity (CDC) through
the constant region of the antibody (Fc), and apoptosis of
target cells directly [6-9]. Recently, some clinical evidence
based on genetic analysis of leukocyte receptor (FcγR) pol-
ymorphisms of cancer patients treated with anti-CD20
IgG1 rituximab and anti-HER2 IgG1 trastuzumab thera-
pies has revealed that ADCC is one of the critical mecha-
nisms responsible for the clinical efficacy of these
therapeutic antibodies [10-14]. A significant correlation
has also been reported between the clinical responses to
the therapies and the low-affinity FcγR polymorphisms in
rituximab-treated patients of systemic lupus erythemato-
sus (SLE) and Waldenstrom's macroglobulinemia, in
Crohn's disease patients treated with anti-TNF-α IgG1 inf-
liximab, and in pregnant women with fetal hemolytic dis-
ease treated with anti-RhD [12,15-17]. Hence, ADCC
enhancement technology is expected to play a key role in
the development of therapeutic antibodies with improved
clinical efficacy. Indeed, a number of preclinical and clin-
ical trials using such non-fucosylated antibody therapeu-
tics are now underway.
Although various therapeutic antibodies confer great ben-
efits to patients, they also present serious issues of cost-
effective performance; as it has been pointed out, some of
the currently approved therapeutic antibodies are unable
to induce more than remission of cancer despite the fairly
high cost of the therapy. Recently, the inhibition of thera-
peutic-antibody ADCC by plasma IgG, probably through
competition for binding of the therapeutics to FcγR on
effector cells, is found to be at least partly responsible for
the large dose requirement in antibody therapies [18,19].
On the other hand, fully non-fucosylated anti-CD20
rituximab is shown to exhibit strong ADCC at lower con-
centrations (10 to 100 ng/mL) with much higher efficacy
than that of its fucosylated counterparts, even in the pres-
ence of plasma IgG [20,21]. However, the basic data elu-
cidating how fully non-fucosylated antibodies show such
a high ADCC in human whole blood have not yet been
disclosed. The precise mechanisms responsible for the
high ADCC mediated by fully non-fucosylated therapeu-
tic antibodies, even in the presence of human plasma,
should be explained based on direct evidence of non-fuc-
osylated antibody action in human blood. Understanding
the behavioral differences between non-fucosylated and
fucosylated therapeutic antibodies in human blood can
provide a new clue for improving antibody therapies.
In this study, we explored the mechanisms by which non-
fucosylated therapeutic antibodies induce much higher
ADCC in human blood than do fucosylated therapeutics.
As a model of human in vivo, we employed a human B-cell
depletion assay with anti-CD20 IgG1 rituximab, and
focused on the actual binding to the two key cellular com-
ponents of effector and target cells in human blood:
namely, the binding through FcγRIIIa to natural killer
(NK) cells (effector side interaction) and the binding
through the antigen to target cells (target side interaction).
This ex vivo model was considered to be suitable for ana-
lyzing the functions of therapeutic antibodies in human
blood because it has been shown to reflect well the in vivo
intravascular environment [18,20,22,23]. Here, we dis-
cuss two ingenious mechanisms underlying the enhanced
ADCC efficacy of fully non-fucosylated therapeutic anti-
bodies in human blood, based on data reflecting the
actions of antibody molecules in human blood.
Methods
Blood donors
Blood donors were randomly selected from healthy vol-
unteers registered at Tokyo Research Laboratories, Kyowa
Hakko, Co., Ltd. All donors gave written informed con-
sent before the analyses. Human serum samples collected
from 12 individuals (5 women and 7 men, aged 20 to 57
years) with written informed consent were purchased
from ProMedDx (Norton, MA).
Antibodies
Non-fucosylated and fucosylated anti-CD20 IgG1s, and a
triple amino acid-substituted anti-CD20 IgG1 rituximab
mutant (S239D/S298A/I332E) were prepared as
described previously [20,24]. Anti-CD20 IgG1s were
biotinylated using EZ-Link Sulfo-NHS-LC-biotin (Pierce,
Rock-ford, IL) according to the manufacturer's instruc-
tions. The labeled anti-CD20s were purified by dialysis
with Spectra/Pro® 2 Dialysis Membrane (Spectrum Labo-
ratories, Inc., Rancho Dominguez, CA) in phosphate-buff-
ered saline (PBS). The antigen-binding activity of the
labeled anti-CD20s was measured by CD20-binding
ELISA [25], and confirmed to be equivalent to that of the
non-labeled anti-CD20 and rituximab (Rituxan) pur-
chased from Genentech, Inc. (South San Francisco, CA)
prior to use.
Analyses of human endogenous IgG1
Human endogenous IgG was fractionated from human
serum samples of 20 healthy donors using MabSelect
(Amersham Biosciences, Piscataway, NJ). The bound frac-
tion contained IgG1, 2 and 4, whereas the bulk of IgG3
passed through the column. The pool of IgG1, 2, and 4,BMC Cancer 2009, 9:58 http://www.biomedcentral.com/1471-2407/9/58
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eluted from the MabSelect, was stored in 10 mM citrate
buffer pH 6.0 with 0.15 M NaCl. The concentration of
endogenous IgG1 in the pool was measured by human
IgG1-specific ELISA using peroxidase-conjugated mouse
anti-human IgG1 monoclonal antibodies (clone HP6069;
Zymed Laboratories, South San Francisco, CA) as previ-
ously described [26]. The Fc of the IgG1 was prepared
from the pool by a common procedure including papain
cleavage, purification with MabSelect, and Superose12
(Amersham Biosciences) gel filtration chromatography to
analyze the Fc oligosaccharide structure.
Analyses of antibody-derived N-linked oligosaccharides
N-linked oligosaccharides were released by digestion of
the purified anti-CD20 IgG1 and the Fc of human endog-
enous IgG1 with N-glycosidase F (Takara, Shiga, Japan).
The released carbohydrates were analyzed by matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) with a positive-ion mode
as described previously [27]. Monosaccharide composi-
tion of IgG1 was characterized by modified high-perform-
ance anion exchange chromatography (HPAEC) analysis
as previously described [28].
Antigen binding on target cells
Human peripheral blood mononuclear cells (PBMC)
were prepared from healthy donors, and washed and
resuspended in stain buffer (PBS containing 1% bovine
serum albumin (BSA)). B cells were purified from PBMC
by B Cell Isolation Kit II (Miltenyi Biotec, Bergisch-Glad-
bach, Germany) as negative fractions passed through a
magnetic separation column (autoMACS™; Miltenyi Bio-
tec). The purity of isolated B cells was more than 95%, as
assessed by flow cytometer FACSCalibur (BD Biosciences,
San Jose, CA) using anti-CD19-FITC (clone J4.119; Beck-
man Coulter, Coulter, Miami, FL). Purified B cells were
adjusted to 1 × 106 cells/mL and incubated with serial
dilutions (0.001 to 10 μg/mL) of anti-CD20 s for 30 min
to 4 h at 37°C. The cells were then washed, and incubated
with phycoerythrin (PE)-conjugated mouse anti-human
IgG (BD Biosciences Pharmingen, San Diego, CA) for 30
min at 4°C to detect binding of anti-CD20s on B cells
using FACSCalibur.
Ex vivo B-cell depletion assay
Heparinized peripheral blood samples from healthy
donors were incubated with serial dilutions (0.0001 to 10
μg/mL) of anti-CD20s for 4 h at 37°C, and CD19+CD2- B
cells were analyzed by FACSCalibur as described previ-
ously [20]. The cytotoxicity against CD19+CD2- B cells
was calculated according to the following formula:
Cytotoxicity (%) = (1 - (%CD19+CD2- B cells treated with 
anti-CD20 IgG1)/(%CD19+CD2- B cells treated with 
PBS)) × 100.
Antigen-binding analysis in human blood
The antigen-binding activity of anti-CD20s on human B
cells in human whole blood was analyzed by competitive
inhibition assay with biotin-labeled anti-CD20 using flow
cytometry. Heparinized peripheral blood from healthy
donors was incubated simultaneously with 3.3 μg/mL of
the biotinylated anti-CD20 (fucosylated or non-fuco-
sylated) and serial dilutions (1 to 100 μg/mL) of non-
labeled competitor anti-CD20s on ice for 30 min. Aliq-
uots of samples were washed once with the stain buffer,
and incubated with PE-conjugated streptavidin (Beckman
Coulter) and anti-CD19-FITC on ice for 30 min. Stained
cells were suspended in FACS Lysing Solution (BD Bio-
sciences) to lyse erythrocytes and washed twice with the
stain buffer. The binding intensity of biotinylated anti-
CD20 to B cells detected with CD19+ was analyzed by
FACSCalibur.
FcγRIIIa-binding analysis in human blood
The FcγRIIIa-binding activity of anti-CD20s on human
NK cells in human whole blood was analyzed by flow
cytometry using anti-idiotype monoclonal antibodies
against rituximab [29]. Heparinized peripheral blood
samples from healthy donors or samples, depleted of
plasma by washing and reconstituted with stain buffer,
were incubated with serial dilutions (1.1 to 30 μg/mL) of
anti-CD20s on ice for 30 min. After washing with the stain
buffer, the cells were stained with anti-rituximab-FITC
(clone MB2 A4, Abcam, Cambridge, UK) to detect anti-
CD20s bound to FcγR, and simultaneously stained with
PE-Cyanin 5.1 (PC5)-labeled anti-CD3 antibodies PC5
(clone UCHT1, Beckman Coulter) and PE-labeled anti-
CD56 antibodies (clone N901, Beckman Coulter) to
detect CD3-CD56+ NK cells. Following incubation on ice
for 30 min, the intensity of anti-rituximab-FITC bound to
NK cells detected with CD3-CD56+ was analyzed by FAC-
SCalibur. To analyze whether or not the binding of anti-
CD20 to NK cells was through FcγRIIIa, samples were
incubated simultaneously with 100 μg/mL of non-labeled
anti-CD16 antibodies (clone 3G8, Ancell, Bayport, MN)
and 10 μg/mL of non-fucosylated anti-CD20 on ice for 30
min, and the anti-CD20 bound to NK cells was analyzed
by FACSCalibur. Mouse IgG1 (clone 15H6s, Beckman
Coulter) was used as an isotype control.
In vitro ADCC assay
Human PBMC, including effector NK cells and target B
cells, was prepared from healthy donors and suspended in
RPMI 1640 medium supplemented with 5% fetal bovine
serum. Then, the PBMC suspension (240 μL including 0.6
× 106 cells), auto plasma or commercial human serum
(300 μL), and serial dilutions (0.001 to 10 μg/mL) of anti-
CD20s (60 μL in PBS) were dispensed into each well of
24-well culture plates and incubated at 37°C for 4 h. The
cytotoxicity against CD19+CD2- B cells was estimated asBMC Cancer 2009, 9:58 http://www.biomedcentral.com/1471-2407/9/58
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described above in an ex vivo B-cell depletion assay. The
ADCC inhibitory activity of human serum was calculated
according to the following formula:
ADCC inhibition (%) = (1 - (cytotoxicity (%) with human 
serum)/(cytotoxicity (%) without human serum)) × 100.
Results
Generation of non-fucosylated and fucosylated anti-
CD20s
Non-fucosylated and fucosylated anti-CD20s are com-
posed of amino acid sequences identical to that of rituxi-
mab, and thus it was confirmed that they exhibited equal
CD20 binding activity using the antigen-binding ELISA
[20]. The anti-CD20 variant (S239D/S298A/I332E) also
bound to the CD20 antigen equally as well as rituximab
because the variable region of both forms had the same
amino acid sequence [24]. Thus, these anti-CD20s also
showed equal binding to human B cells in flow cytometry
analyses, and down-modulation of CD20 by anti-CD20s
was not observed during 4h-incubation (Fig. 1). Oligosac-
charide analysis of the generated anti-CD20s confirmed
that the attached oligosaccharides were of a complex bian-
tennary type and that the IgG1 generated by the FUT8-/-
cell line Ms704 contained no fucose residue (Fig. 2).
Ex vivo ADCC activity of anti-CD20s
To analyze the ex vivo ADCC activity of each anti-CD20,
whole blood samples from two healthy donors (donors 1
and 2) were incubated with serial dilutions of non-fuco-
sylated or fucosylated anti-CD20s (Fig. 3a). Fucosylated
anti-CD20 reduced only about 30% of B cells at 10 μg/mL
in donors 1 and 2. By contrast, non-fucosylated anti-
CD20 showed more than 100-fold potent B-cell depletion
activity with much higher efficacy than its fucosylated
counterpart in both individuals, with EC50 values of 0.001
μg/mL (in donor 1) and 0.01 μg/mL (in donor 2). The
anti-CD20 variant (S239D/S298A/I332E), having higher
FcγRIIIa-binding activity than fucosylated wild type anti-
CD20, also showed high ex vivo ADCC almost identical to
that of non-fucosylated wild type anti-CD20 in both indi-
viduals, consistent with the findings of previous reports
[21,24]. A series of mixtures composed of non-fucosylated
and fucosylated anti-CD20s at different ratios was pre-
pared by adding serial 3-fold amounts of fucosylated anti-
CD20 to a fixed amount (0.11 μg/mL) of non-fucosylated
anti-CD20, and ex vivo B-cell depletion activities of the
Antigen binding activity of anti-CD20 IgG1 rituximab variants to target B cells Figure 1
Antigen binding activity of anti-CD20 IgG1 rituximab variants to target B cells. Purified human B cells from healthy 
donor 1 were incubated with anti-CD20 IgG1 rituximab (open square) and its variants (fucosylated (closed circle), non-fuco-
sylated (open circle), triple amino acid-substituted mutant S239D/S298A/I332E (closed square)) at indicated concentrations at 
37°C for 30 min (a), or at 3.3 μg/mL at 37°C for 30, 120 and 240 minutes (b). In both experiments, anti-CD20s bound to 
CD20 on B cells were detected with PE-conjugated mouse anti-human IgG. Mean fluorescence intensity is indicated by mean 
values ± SD of triplicates.
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mixtures were measured (Fig. 3b, donor 3). The concen-
tration of 0.11 μg/mL was chosen to be the minimum
dose showing saturable ex vivo efficacy in the donor blood
(donor 3). There was no significant change observed by
the addition of further non-fucosylated anti-CD20, as the
initial dose already reached the saturable effective dose.
The addition of the fucosylated anti-CD20 to non-fuco-
sylated anti-CD20 depressed the ex vivo B-cell depletion
activity in a dose-dependent manner; thus, the ex vivo B-
cell depletion activity of the mixture consisting of fuco-
sylated and non-fucosylated anti-CD20s did not reach
that of the antibody sample consisting of non-fucosylated
anti-CD20 alone.
Inhibitory effect of human plasma on binding of anti-
CD20s to FcγRIIIa on NK cells
To address the reason why non-fucosylated anti-CD20
induced a higher ex vivo ADCC efficacy than did fuco-
sylated anti-CD20, the binding of anti-CD20s to NK cells
was analyzed in human whole blood matrices using anti-
rituximab-FITC in donor 4, who showed a similar B-cell
depletion pattern with anti-CD20 as donor 2. The binding
of anti-CD20 to NK cells was confirmed to be mediated
mostly through the interaction of the Fc region with FcγRI-
IIa on NK cells since anti-CD16 antibody 3G8 inhibited
the binding (Fig. 4). Non-fucosylated anti-CD20 exhib-
ited markedly stronger binding to NK cells than fuco-
sylated anti-CD20 in terms of the ratio of anti-CD20
positive NK cells and the staining intensity of anti-CD20
per NK cell (Fig. 5). It is worth noting that non-fuco-
sylated and variant (S239D/S298A/I332E) anti-CD20s
still retained high binding activity for NK cells in the pres-
ence of plasma, while the binding of fucosylated anti-
CD20 to NK cells was almost abolished in the presence of
plasma.
Inhibitory effect of fucosylated anti-CD20 on binding of 
non-fucosylated anti-CD20 to the target antigen on B cells
The binding of anti-CD20 to target B cells was also ana-
lyzed in human whole blood matrices (donor 5) using a
competitive inhibition assay with biotin-labeled anti-
CD20s. Biotinylated anti-CD20s that retained antigen-
binding activity comparable to that of non-labeled anti-
CD20 were employed in the competitive inhibition assay.
As shown in Fig. 6, the ex vivo binding of biotinylated anti-
CD20 (3.3 μg/mL) was inhibited by non-labeled anti-
CD20 in a dose-dependent manner, irrespective of fuco-
sylation or amino acid mutation of the Fc region of the
added anti-CD20; i.e., fucosylated, non-fucosylated and
triple amino-acid-substituted anti-CD20s exhibited an
identical antigen-binding activity on the target B cells in
human whole blood.
Oligosaccharide analysis of the anti-CD20 IgG1 rituximab variants Figure 2
Oligosaccharide analysis of the anti-CD20 IgG1 rituximab variants. a Each value of composition is the relative amount 
in total complex-type oligosaccharides detected. b Schematic descriptions of oligosaccharides correspond to: galactose (trian-
gle), N-acetylglucosamine (GlcNAc) (circle), mannose (square), and core fucose (star). c Relative amount of non-fucosylated oli-
gosaccharides. d Data from reference 28. e n.d.: not detected (less than 2.0%).
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Ex vivo B-cell depletion activity of anti-CD20 IgG1 rituximab variants in a whole blood matrix Figure 3
Ex vivo B-cell depletion activity of anti-CD20 IgG1 rituximab variants in a whole blood matrix. (a) Heparinized 
peripheral blood from healthy donors 1 and 2 were incubated with serial dilutions of anti-CD20 IgG1 rituximab variants (fuco-
sylated (closed circle), non-fucosylated (open circle), triple amino acid-substituted mutant S239D/S298A/I332E (closed 
square)). No significant difference in cytotoxicity was observed between non-fucosylated and triple amino acid-substituted 
mutant S239D/S298A/I332E by paired t-test. (b) Non-fucosylated anti-CD20 was added to the whole blood sample from donor 
3 at 0.11 μg/mL (white column). Non-fucosylated (gray column) or fucosylated (black column) anti-CD20 was further added to 
the reaction at final concentrations as indicated. In both experiments, the remaining B cells after 4-h treatment were stained 
with anti-CD19-FITC, and the samples were analyzed on a flow cytometer to quantify the number of B cells. B-cell depletion is 
represented as cytotoxicity (%) as described in Materials and Methods.
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Inhibitory effect of individual human plasma on in vitro 
ADCC induced by anti-CD20s
The inhibitory effect of human plasma on ADCC induced
by anti-CD20s was confirmed by an in vitro ADCC assay
with purified PBMC in the presence or absence of plasma
(donors 6 and 7). In this assay, fucosylated or non-fuco-
sylated anti-CD20 (1 μg/mL) was employed as an ADCC
inducer against target B cells, and B-cell depletion medi-
ated by the ADCC was measured by flow cytometry. The
ADCC of anti-CD20s was inhibited by autologous plasma
(greatly in fucosylated and slightly in non-fucosylated
anti-CD20s) (Fig. 7a). However, in the absence of plasma,
fucosylated anti-CD20 showed quite high ADCC (exceed-
ing 40% cytotoxicity) compared with the case in the pres-
ence of plasma, and this value was fairly close to that of
non-fucosylated anti-CD20. Next, we focused on whether
or not individual differences in endogenous human
plasma modulate the inhibitory effects on ADCC induced
by fucosylated anti-CD20 (1 μg/mL) (Fig. 7b, c, d, donor
8). Human sera from 12 healthy individuals were
employed; the individual sera themselves were confirmed
not to show any detectable cytotoxic activity against
human B cells in this experiment. Although the 12 indi-
vidual sera displayed slight differences in terms of IgG1
concentration (5.3 to 7.5 mg/mL) and the relative amount
of non-fucosylated Fc oligosaccharides (1.2 to 6.5%), con-
sistent with previous reports [30,31], the intensity of
inhibitory activity of individual serum against the ADCC
of fucosylated anti-CD20 did not significantly correlate
with these differences.
Discussion
Currently, the application of human IgG1 fully lacking
core fucose in the Fc oligosaccharides is expected to be a
promising approach for next-generation therapeutic anti-
bodies with improved efficacy, even when administrated
at low doses in humans in vivo. In order to develop fully
non-fucosylated therapeutic antibodies as new medicine,
the pharmacodynamic characteristics of the antibodies
should be elucidated: how fully non-fucosylated antibod-
ies effectively mediate two key cellular component inter-
actions of effector and target cells to exercise high ADCC
and what the differences are between non-fucosylated and
fucosylated antibodies in these actions. In this study, we
addressed non-fucosylated antibody actions in human
blood.
Firstly, we were surprised that the binding of fucosylated
antibodies to NK cells was not detected, even at the high
concentration of 30 μg/mL, in the presence of human
plasma (Fig. 5). A common feature of the antibody thera-
pies against cancers is that their anti-tumor efficacies typ-
ically require weekly administration of a high dose (2–8
mg/kg) over several months to maintain effective serum
concentrations exceeding 10 μg/mL [32-34]. Thus, it is
realized that currently-licensed therapeutic antibodies
mostly do not bind to NK cells in human blood after
administration. On the other hand, the binding of anti-
bodies to target cells was detected at a concentration of 3.3
μg/mL, irrespective of the presence of human plasma (Fig.
1, 6). The antigen binding of therapeutic antibodies to tar-
get cells appears to be simply determined by their specifi-
city and affinity. In current antibody therapies,
administered therapeutic antibodies seem to have suffi-
cient capability to concentrate in the target cells accessible
from the bloodstream, but not to capture effector cells in
the target sites effectively.
We confirmed the inhibitory effects of human serum IgG
on the ADCC of therapeutic antibodies, consistent with
previous reports [18-21,35]. ADCC of fucosylated anti-
bodies was significantly affected by human plasma IgG
(Fig. 7a). In contrast, non-fucosylated antibodies showed
much stronger binding to FcγRIIIa on NK cells, even in the
presence of human plasma IgG, resulting in much higher
potency and efficacy of non-fucosylated compared to fuc-
osylated antibodies (Fig. 3a). In our experiments, the con-
centrations of therapeutic antibodies required for
inducing ex vivo ADCC and binding to FcγRIIIa on NK
cells were not necessarily consistent. This discrepancy
seemed to reflect the fact that human serum IgG bound to
FcγRIIIa on NK cells might be more effectively displaced
by therapeutic antibodies bound to the surface of target
Ex vivo binding of non-fucosylated anti-CD20 IgG1 rituximab  to FcγRIIIa on NK cells Figure 4
Ex vivo binding of non-fucosylated anti-CD20 IgG1 
rituximab to FcγRIIIa on NK cells. Heparinized periph-
eral blood from donor 4 was incubated with non-fucosylated 
anti-CD20 IgG1 10 μg/mL (blank histogram) or stain buffer 
alone (filled histogram), in the presence of anti-CD16 anti-
body 3G8 (bold line) or mouse IgG1 isotype control (solid 
line). CD3-CD56+ NK cells were gated in the histogram. The 
binding of non-fucosylated anti-CD20 IgG1 to FcγRIIIa on NK 
cells was detected by anti-rituximab-FITC.
C
o
u
n
t
Anti-rituximab-FITCBMC Cancer 2009, 9:58 http://www.biomedcentral.com/1471-2407/9/58
Page 8 of 12
(page number not for citation purposes)
cells than unbound forms, possibly due to an avidity
effect via formation of a polyvalent FcγRIIIa-binding
matrix, and consequently promoting recruitment of NK
cells. Interestingly, a triple amino acid-substituted mutant
(S239D/S298A/I332E) showed almost identical ex vivo
ADCC and NK cell binding to that of the non-fucosylated
wild type (Fig. 3a, 5), although the mutant was shown to
have higher affinity than the non-fucosylated wild type for
recombinant FcγRIIIa in vitro [24]. The binding affinity
estimated by solid-phase assay with recombinant protein
forms might not necessarily be the same as the affinity to
the native structure forms on the cell surface; thus, the
equivalency in anti-CD20 efficacy was observed.
Before starting these experiments, we speculated that the
concentration of human plasma IgG1 is so huge that its
fucosylation level might affect the inhibitory activity of
ADCC induced by therapeutic antibodies, even though
the proportion of non-fucosylated IgG1 is very low.
Indeed, human plasma contains 5 mg/mL of endogenous
IgG1 [30], which is approximately 100-fold higher than
the serum trough concentration of rituximab [32]. How-
ever, contrary to our speculation, we could not detect any
significant difference caused by variations in serum IgG1
fucosylation levels in healthy individuals (Fig. 7)
although individual human serum IgG1 from 12 healthy
donors showed slight variations in the concentration (5.3
to 7.5 mg/mL) and the content of non-fucosylated oli-
gosaccharide structures (1.2 to 6.5%). Factors other than
endogenous IgG1 concentration and fucosylation levels,
such as variations of other endogenous IgG subclasses,
might also be involved in the ADCC inhibitory activity of
human serum IgG from healthy individuals. Some leuke-
mia patients are reported to increase their relative levels of
Ex vivo binding activity of anti-CD20 IgG1 rituximab variants to FcγRIIIa on NK cells Figure 5
Ex vivo binding activity of anti-CD20 IgG1 rituximab variants to FcγRIIIa on NK cells. Heparinized peripheral blood 
from donor 4, or blood depleted of auto-plasma by washing and reconstitution with stain buffer, was incubated with serial dilu-
tions of anti-CD20 IgG1s. Anti-CD20 IgG1 rituximab variants bound to FcγRIIIa on CD3-CD56+ NK cells after incubation on 
ice for 30 min were detected by anti-rituximab-FITC.
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non-fucosylated Fc oligosaccharides [36]. It is still
thought to be interesting to explore whether individual
patient variations in endogenous IgG1 fucosylation level
might affect the efficacy of antibody therapies.
We also confirmed that enhanced ex vivo ADCC of non-
fucosylated therapeutic antibodies is inhibited by their
fucosylated counterparts, consistent with previous reports
[20,21,27]. In our experiments, down-modulation of
CD20 antigen on B cells mediated by anti-CD20 was not
observed (Fig. 1), and simple competition for binding to
the antigens on target B cells between fucosylated and
non-fucosylated anti-CD20s was detected in human
blood (Fig. 6), resulting in inhibition of the enhanced
ADCC of non-fucosylated anti-CD20 by fucosylated anti-
CD20. Thus, the mechanism by which ADCC induced by
non-fucosylated antibodies is inhibited by fucosylated
forms is mainly through competition of the two forms for
the antigens on target cells. In other words, the density of
the non-fucosylated form on the target cells is reduced by
fucosylated form occupation, which causes an effect to
shed the target antigens from capture by the therapeutic
agent having high ADCC activity even in plasma. To over-
come interference from human plasma IgG and recruit
NK cells to the target cells effectively, the key is to coat the
target cells with therapeutic agents having higher binding
affinity to FcγRIIIa than plasma IgG, such as fully non-fuc-
osylated IgG1. The non-fucosylated form of IgG1 is a nat-
ural component in human serum IgG, and is also
observed as a trace ingredient in currently-licensed thera-
peutic antibodies [37-40]. It will be great benefits for
patients if the proportion of the non-fucosylated form is
increased in antibody therapeutics.
Ex vivo binding activity of anti-CD20 IgG1 rituximab variants to CD20 on B cells Figure 6
Ex vivo binding activity of anti-CD20 IgG1 rituximab variants to CD20 on B cells. Heparinized peripheral blood 
from donor 5 was incubated simultaneously with 3.3 μg/mL of biotinylated anti-CD20 IgG1 and serial dilutions of non-labeled 
competitor anti-CD20 IgG1 rituximab on ice for 30 min. The remaining biotinylated anti-CD20 IgG1 bound to CD20+ B cell 
was detected by streptavidin-PE using FACS analysis. Data for the binding of biotinylated fucosylated anti-CD20 are shown.
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Conclusion
Our findings demonstrate that removal of fucosylated
antibody ingredients from antibody therapeutics elicits
high ADCC, even in human blood, via two mechanisms:
namely, by evading the inhibitory effects both of plasma
IgG on the binding of FcγRIIIa on NK cells and of fuco-
sylated counterparts on the binding of the antigen on tar-
get cells. Thus, antibody therapy consisting of fully non-
fucosylated IgG1, not including the fucosylated form, is
worth to apply as next-generation antibody therapy with
improved efficacy at a reduced dose for patients, which
will have a great impact especially on human cancer ther-
apy based on the ADCC mechanism.
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